Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study  Dr Jack R W Brownrigg, MRCS, Cian O Hughes, MRCS, David Burleigh, MSc, Alan Karthikesalingam, PhD, Benjamin O Patterson, PhD, Peter J Holt, PhD, Prof Matthew M Thompson, MD, Prof Simon de Lusignan, MD, Prof Kausik K Ray, MD, Prof Robert J Hinchliffe, MD  The Lancet Diabetes & Endocrinology  Volume 4, Issue 7, Pages 588-597 (July 2016) DOI: 10.1016/S2213-8587(16)30057-2 Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 1 Unadjusted freedom from the primary outcome (A), admission to hospital for heart failure (B), and cardiovascular mortality (C) by cumulative burden of microvascular disease The primary outcome measure was cardiovascular mortality, non-fatal myocardial infarction, or non-fatal ischaemic stroke. Log-rank test for the linear association between cumulative burden of microvascular disease for the primary outcome, p<0·0001; admission to hospital for heart failure, p<0·0001; and for all-cause mortality, p<0·0001. The Lancet Diabetes & Endocrinology 2016 4, 588-597DOI: (10.1016/S2213-8587(16)30057-2) Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 2 Adjusted hazard ratio for the primary outcome (A), admission to hospital for heart failure (B), and cardiovascular mortality (C) by cumulative burden of microvascular disease and per 1 SD difference in values for established risk factors* The primary outcome measure was cardiovascular mortality, non-fatal myocardial infarction, or non-fatal ischaemic stroke. 1 SD of each established risk factor is: blood pressure 13·5/8·4 mm Hg; LDL cholesterol 0·9 mmol/L; BMI 6·3 kg/m2; HbA1c 1·3% (14·2 mmol/mol). *Adjusted for age, sex, systolic blood pressure, diastolic blood pressure, LDL cholesterol, HDL cholesterol, HbA1c, BMI, duration of diabetes, smoking status, antiplatelet therapy, lipid-lowering treatment, RAS blockade, other blood pressure treatment, ethnicity, and Index of Multiple Deprivation. The Lancet Diabetes & Endocrinology 2016 4, 588-597DOI: (10.1016/S2213-8587(16)30057-2) Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 3 Adjusted event rates for the primary outcome by cumulative burden of microvascular disease and established risk factor goals* The primary outcome measure was cardiovascular mortality, non-fatal myocardial infarction, or non-fatal ischaemic stroke. *Adjusted for age, sex, systolic blood pressure, diastolic blood pressure, LDL cholesterol, HDL cholesterol, HbA1c, BMI, duration of diabetes, smoking status, antiplatelet therapy, lipid-lowering treatment, RAS blockade, any blood pressure treatment, ethnicity, and Index of Multiple Deprivation. The Lancet Diabetes & Endocrinology 2016 4, 588-597DOI: (10.1016/S2213-8587(16)30057-2) Copyright © 2016 Elsevier Ltd Terms and Conditions